Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech

March 14, 2019 admin CEO Interview, Healthcare Comments Off on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech

 

 

 

Roger Tung, CEO

 

 

 

 

 

 

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Interview with Roger Tung, CEO discussing the company’s deuterium chemistry platform for creating new drugs which have superior properties—including enhanced clinical safety, tolerability or efficacy—based on compounds that have established pharmacological activity. The company’s current pipeline has 3 drugs which have “blockbuster potential” for treating, alopecia areata,  schizophrenia, and Alzheimers agitation. 

Investor Presentation

Concert-Presentation-Feb2019-FINAL

 

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

September 9, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Sept. 09, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

CytoDyn (OTC: CYDY) to Present at RHK Capital 2019 Disruptive Growth Conference

August 29, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) to Present at RHK Capital 2019 Disruptive Growth Conference

VANCOUVER, Washington, Aug. 29, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

CEO Interview

BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

December 23, 2018 admin CEO Interview, Healthcare Comments Off on BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials

      BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company’s advancements in developing stem cell therapies to treat neurodegenerative diseases. The company’s pipeline includes a lead indication for ALS- Amyotrophic Lateral […]